Porphyria and Menopause

What's UP Doc?
Written By Dr. Karl Anderson

What's UP Doc? Is a regular column where we feature a patient question along with a response from a member of the UPA Scientific Advisory Board.

How will menopause affect my porphyria? Are estrogen treatments for menopause safe?

Today’s response comes from Dr. Karl Anderson of University of Texas Medical Branch in Galveston, TX. We received multiple questions about how menopause might affect several types of porphyria, so we asked Dr. Anderson to tackle them all.

Select your type of porphyria to see Dr. Anderson’s response!

  • It is common for women with acute hepatic porphyria to have fewer attacks and symptoms after menopause. This is because hormone increases associated with the menstrual cycle no longer occur after menopause.  Increased levels of progesterone in the second half of the cycle are especially likely to cause attacks. 

    So, in general you can expect fewer porphyria symptoms after menopause.  However, there are exceptions, and some women continue to have attacks or even have their first attack after menopause. 

    Estrogens are less likely than progesterone to contribute to attacks.  However, estrogens are still often listed as unsafe.  If estrogen replacement is needed after menopause, it is best if it is delivered through a skin patch instead of taken orally, because this reduces the amount delivered directly to the liver. 

  • To the best of my knowledge, changes in hormones that come with menopause (or with puberty) don’t have any impact on EPP or XLP. Likewise, it is unlikely that menopause will have any impact- for better or for worse- on your porphyria.  Excess porphyrins in these porphyrias come from the bone marrow rather than the liver, and progesterone and estrogens affect the liver but do not have the same effects on the bone marrow. Description text goes here

  • Menopause is unlikely to have an impact on PCT (see this What’s UP Doc? response on the topic).  

    Although PCT is an hepatic porphyria, the effects of hormones are quite different from AIP, VP and HCP.  Oral estrogens are often a causative factor in women with PCT, while progesterone-related products are not.  Estrogens given by skin patch are safer in PCT compared to oral estrogens, because exposure to the liver is less. 

Thank you to Dr. Karl Anderson for this What's UP Doc? answer!

Do you have a question for a porphyria expert? Send it to info@porphyria.org.

 

Check out related What’s UP Doc? Responses

Porphyria Spotlight
Urine Porphyrins for Diagnosis
Urine Porphyrins for Diagnosis

Question: I think I might have Acute Intermittent Porphyria (AIP). My doctor ordered a urine porphyrin test, my porphyrins were high but then I was told that the results aren't considered diagnostic. Why not? And what tests should my doctor order?

Porphyria and Menopause
Porphyria and Menopause

Question: How will menopause affect my porphyria? Are estrogen treatments for menopause safe?

Surgery precautions and cutaneous porphyrias
Surgery precautions and cutaneous porphyrias

Question: I am having a planned laparoscopic surgery next week.  Should there be a filter on the light on the laparoscope?  If so, would you be able to tell me what filter would need to be used?  Can you also tell me what filters would be needed for the surgery lights in the operating room?

Acute porphyria and liver tests
Acute porphyria and liver tests

Question: If you have acute porphyria, why is it important to have your liver function checked annually? What can you do to prevent issues with your liver?

Dr. Karl Anderson

Dr. Anderson is a graduate of the Johns Hopkins University School of Medicine, completed residency in internal medicine at Vanderbilt University Hospital and the New York Hospital-Cornell Medical Center, followed by training in gastroenterology also at Cornell. He was a member of the faculty at the Rockefeller University, Cornell University Medical College and New York Medical College before coming to the University of Texas Medical Branch at Galveston in 1987, where he is a Professor in the Department of Internal Medicine (Division of Gastroenterology and Hepatology).

He directs the Porphyria Laboratory and Center at UTMB, which is part of the NIH-supported Porphyrias Consortium. He is an active clinical investigator with support from the NIH, FDA, foundations and industry. His research focusses on the human porphyrias and their treatment.

Previous

Meet Dr. Karl Anderson
Next

Meet Ariel Lager, UPA Director